Zymeworks Stock Price, News & Analysis

Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has strengthened its Board of Directors with the appointments of Greg Ciongoli and Robert E. Landry, effective August 10, 2025. Both will serve on the Board's audit committee.

Ciongoli, founder of Adiumentum Capital Management, brings extensive healthcare investment and corporate governance experience. Landry contributes over 30 years of financial leadership in pharma and biotech, most recently as CFO at Regeneron Pharmaceuticals.

The appointments come at a crucial time as Zymeworks advances its development programs, including recent regulatory approvals for zanidatamab in the U.S., Europe, and China, and an upcoming HERIZON-GEA-01 topline data readout in Q4 2025. Troy Cox, who served since 2019, has stepped down from the Board.

Zymeworks (NASDAQ:ZYME) reported strong Q2 2025 financial results with $48.7 million in revenue, up from $19.2 million in Q2 2024, and achieved a net income of $2.3 million. The company secured FDA clearance for ZW251's IND application and reported $333.4 million in cash resources as of June 30, 2025.

Key developments include Chinese and European approval for zanidatamab in HER2-positive biliary tract cancer, with Ziihera® generating $5.5 million in net product sales. The company's partner Jazz reported promising long-term data for Ziihera® in gastroesophageal adenocarcinoma, showing median overall survival of 36.5 months. Strategic partnerships with BMS, J&J, and Daiichi Sankyo continue to progress, validating Zymeworks' platform technology.

The company projects cash runway into second half of 2027, supported by milestone payments and partnership revenues.

Zymeworks (NASDAQ:ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW251, a novel antibody-drug conjugate (ADC) targeting hepatocellular carcinoma (HCC). ZW251 is designed to target glypican-3 (GPC3), which is expressed in over 75% of HCC cases.

The drug represents Zymeworks' second ADC utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies demonstrated strong anti-tumor activity across various HCC models and favorable tolerability in non-human primates at doses up to 120 mg/kg. The company plans to initiate Phase 1 clinical trials in 2025.

Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a corporate update.

Additionally, Zymeworks' management will participate in two upcoming investor conferences: the BTIG Virtual Biotechnology Conference on July 29 and the Stifel Biotech Summer Summit from August 11-13, featuring one-on-one meetings and fireside chat presentations.

Zymeworks (NASDAQ: ZYME) has received NMPA approval in China for zanidatamab, making it the first dual HER2-targeted bispecific antibody approved for HER2-positive biliary tract cancer in the region. The conditional approval triggers a $20 million milestone payment from BeOne Medicines, with potential for additional $144 million in development and commercial milestones. Zanidatamab was previously approved by the FDA in November 2024 and received positive CHMP opinion in Europe in April 2025. Under the partnership with BeOne Medicines, Zymeworks has already received $61 million in upfront and milestone payments and is eligible for tiered royalties up to 19.5% of net sales in BeOne's territories. The approval represents a significant advancement for patients with HER2-positive BTC, addressing an area of high unmet medical need.

Zymeworks (NASDAQ: ZYME) announced multiple presentations at upcoming medical conferences showcasing its oncology portfolio. The presentations will take place at the ASCO Annual Meeting (May 31-June 4, 2025) and ESMO Gynaecological Cancers Congress (June 19-21, 2025).

Key highlights include long-term outcomes and survival data for Ziihera® (zanidatamab-hrii) in HER2-positive gastroesophageal cancer, demonstrating the potential of their Azymetric™ platform. Partner presentations from Jazz Pharmaceuticals, Johnson & Johnson, and Daiichi Sankyo will further validate their expertise in multispecific and bispecific antibodies.

The company will also present Trial-in-Progress posters for two clinical candidates: ZW171 (mesothelin x CD3 targeting bispecific T-cell engager) at ASCO and ZW191 (Folate Receptor α-targeting Antibody-Drug Conjugate) at ESMO-Gyn, with enrollment for both trials progressing as planned.

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotech company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in June 2025:

• Jefferies Global Healthcare Conference on June 4 in New York - Management will conduct one-on-one meetings and a fireside chat at 2:35 pm ET
• Goldman Sachs Global Healthcare Conference on June 11 in Miami - Including one-on-one meetings and a fireside chat at 2:00 pm ET
• Citi European Healthcare Conference on June 17 in London - Management will participate in one-on-one meetings

Zymeworks (NASDAQ: ZYME) presented preclinical data for ZW1528, its novel IL-4Rα x IL-33 bispecific molecule targeting respiratory inflammation, at the American Thoracic Society International Conference. The data showed ZW1528's high-affinity binding to both IL-33 and IL-4Rα, effectively blocking IL-4, IL-13, and IL-33 signaling pathways. Key findings demonstrated efficacy in murine models of lung inflammation, extended pharmacokinetics, and biophysical stability at high concentration (150 mg/mL). The company expects to file regulatory submissions for Phase 1 studies in 2H-2026. Additionally, Zymeworks is developing ZW1572 for atopic dermatitis and plans further IND submissions for 2028 and beyond.

Zymeworks (NASDAQ: ZYME) reported its Q1 2025 financial results and corporate updates. The company presented six posters at AACR showcasing their multispecific T cell engager and antibody-drug conjugate platforms. They appointed Dr. Sabeen Mekan as SVP of Clinical Development. Financial highlights include $321.6M in cash resources (vs $324.2M in Dec 2024), with runway into 2H-2027. Q1 revenue was $27.1M (vs $10.0M in Q1 2024), including milestone payments from GSK ($14M) and Daiichi Sankyo ($3.1M). Net loss decreased to $22.6M from $31.7M year-over-year. Their partner Jazz reported $2.0M in Ziihera® sales, generating $0.2M in royalties for Zymeworks. The company continues to advance its pipeline in cancer, inflammation, and autoimmune diseases.